Clinical Trials Logo

Filter by:
NCT ID: NCT03960164 Completed - Skin Wound Clinical Trials

Dermal Regeneration Photosynthetic Matrix

HULK
Start date: April 1, 2019
Phase: Early Phase 1
Study type: Interventional

The aim of the study is to demonstrate that dermal regeneration photosynthetic matrix applied in patients with acute clean skin wound is safe.

NCT ID: NCT03964558 Completed - Heathy Volunteers Clinical Trials

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Acebilustat (CTX-4430)

Start date: April 1, 2019
Phase: Phase 1
Study type: Interventional

This is a single-centre, open-label, non-randomised, single oral dose study in healthy male subjects. It is planned to enroll and dose 6 subjects. Subjects will be admitted to the clinical unit on the evening of Day 1 prior to investigational medicinal product (IMP) administration. Subjects will be dosed on the morning of Day 1 and it is planned that they will remain resident in the clinic until up to 168 hour after dosing (up to Day 8). It is planned that subjects will be released as a group when all subjects have achieved a mass balance cumulative recovery of >90% or if <1% of the dose administered has been collected in urine and faeces within 2 separate, consecutive 24 hour periods.

NCT ID: NCT03969537 Completed - Telemedicine Clinical Trials

Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neurotoxin Injections

Start date: April 1, 2019
Phase:
Study type: Observational

Many cervical dystonia (CD) patients are limited in their ability to travel to the clinic for follow-up in between injection visits. A telemedicine visit at the time of peak effectiveness of neurotoxin treatment may be valuable in informing the neurologist's choice of muscle selection and/or dose for the next injection visit. The primary objective of this study is to investigate both patient and physician satisfaction with the use of our telemedicine tool for this type of follow-up. After assessment of the subject, the neurologist will decide whether or not the telemedicine visit was informative to the upcoming injection visit. Subjects will answer questions at the end of the visit regarding their satisfaction with the follow-up and overall telemedicine communication. The principle investigator will complete a similar survey with additional questions about information gathered from the visit to assess the primary objective. A secure video communications platform will be used for the visit, which will occur 2-4 weeks after the patient's last neurotoxin injection (around the time of peak effectiveness). The investigating neurologist will remotely assess the patient and make notes for the next injection visit.

NCT ID: NCT03971227 Completed - Refractive Errors Clinical Trials

Clinical Evaluation of Acuity 200 (Fluoroxyfocon A) RGP Contact Lens

Acuity 200
Start date: April 1, 2019
Phase: N/A
Study type: Interventional

The objective of this clinical investigation is to collect valid scientific safety and effectiveness data on the Acuity 200 (fluoroxyfocon A) Rigid Gas Permeable Contact Lens, manufactured from a newly developed rigid gas permeable material that is highly permeable to oxygen. The clinical performance data reported from this study is intended to be submitted to the U.S. Food and Drug Administration Center for Devices and Radiological Health (CDRH) in support of a 510(k) premarket notification.

NCT ID: NCT03974490 Completed - Stroke Clinical Trials

Effect of RAS on Balance and Gait After Stroke

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

A rhythmic auditory stimulation intervention may be beneficial in order to improve movement parameters after stroke. Reviews argue that more randomized controlled trials with a control group are needed. Main objective: Evaluate the effect of a rhythmic auditory stimulation on the quality of balance and gait parameters in people with stroke. Methodology: quasi-experimental study. The study has been approved by the hospital ethics committee.

NCT ID: NCT03976726 Completed - Airway Management Clinical Trials

Temperature Dependent Changes in I-gel Masks

Start date: April 1, 2019
Phase:
Study type: Observational

The i-gel® mask is a second generation, single use supraglottic airway device which does not have an inflatable cuff. The cuff consists of a thermoplastic elastomer and its mechanism of sealing still remains unclear. Various theories such as temperature-dependent changes in hardness and volume expansion as well as fluid absorption have been discussed.

NCT ID: NCT03980093 Completed - Breast Cancer Clinical Trials

The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

This pilot trial compares two online interventions to improve adherence to anti-hormonal medication among women with the most common form of breast cancer (estrogen receptor-positive).

NCT ID: NCT03980574 Completed - Heart Failure Clinical Trials

Dietary Supplementation in Heart Failure

R-DRINK
Start date: April 1, 2019
Phase: N/A
Study type: Interventional

A single-center, double-blind, placebo-controlled, cross-over study pilot study comparing R Drink vs. placebo in 60 heart failure patients. Half of the participants will also have diabetes mellitus. The 60 patients will be distributed among three arms. Total distance walked in six minutes and hospital readmission rates will be examined. Eligible heart failure patients include those with systolic or diastolic heart failure and diabetes mellitus can be Type I or II. All patients will continue on their standard heart failure and diabetes therapies while they participate in the study.

NCT ID: NCT03980704 Completed - General Surgery Clinical Trials

Preoperative High Protein vs Immunodiet in Surgical Cancer Patients

Preop immuno
Start date: April 1, 2019
Phase: Phase 4
Study type: Interventional

Immunomodulating nutrition is supposed to reduce the number of complications and the legnth of the hospital stay during the postoperative period in patients after major gastrointestinal surgery. The aim of the study is to assess the clinical effect of immunomodulating oral nutrition in patients undergoing resection for gastrointestinal cancer in the group of well-nourished patients.

NCT ID: NCT03992703 Completed - Clinical trials for Bacterial Infections

Clinical Impact of Rapid AST Directly From Blood Cultures

MHR-BC
Start date: April 1, 2019
Phase:
Study type: Observational

Bacteremia is defined as pathogenic bacteria presence in blood as evidenced by positive blood cultures. These bacteremia have significant consequences in terms of morbidity and mortality (ref. 1,2,3). They can lead to a state of septic shock that is life-threatening for the patient and must be treated as a matter of urgency. Any delay in treatment is detrimental to the patient. Management is based on prescription of probabilistic antibiotic therapy as soon as bacteremia is suspected. At the Groupe Hospitalier Paris Saint Joseph (GHPSJ), as soon as a blood culture is known to be positive, the Mobile Clinical Microbiology Unit (UMMC) is notified in real time. The UMMC infectiologist, in consultation with the microbiologist, evaluates microbiological data and compares them with clinical data in order to prescribe probabilistic antibiotic therapy in the patient's bed. The possible adaptation of antibiotic treatment then depends on the results of antibiotic susceptibility test. Early adaptation of antibiotic treatment to antibiotic susceptibility data, to reassess ineffective treatment or to reduce antibiotic therapy spectrum, significantly improves patient prognosis: it is therefore important that the laboratory makes antibiotic susceptibility test results available to the clinician as early as possible.